Vaccines

关注
A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
AI 生成的图像

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

由 AI 报道 AI 生成的图像 事实核查

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Jorge Carrasco, president of the Chilean Society of Pediatrics, said flu vaccine coverage for children under five stands at only 60.54%, below the 80% target.

由 AI 报道

Australia has recorded 230 cases of diphtheria and one related death this year. The outbreak is concentrated in remote Indigenous communities across several states.

Researchers led by Flinders University have identified the molecular trigger behind a rare blood clotting disorder linked to adenovirus-based COVID-19 vaccines and infections. The immune system mistakes an adenovirus protein for the human blood protein PF4, leading to harmful antibodies in extremely rare cases. The discovery, detailed in the New England Journal of Medicine, paves the way for safer vaccines.

由 AI 报道

Small-scale farmers in South Africa's Eastern Cape have voiced frustration over inaccessible foot-and-mouth disease (FMD) vaccines, saying they have sought help from the Department of Agriculture without success.

Researchers at Northwestern University have developed a more effective therapeutic vaccine for HPV-related cancers by rearranging components in a DNA-based nanoparticle. This structural adjustment significantly enhances the immune system's ability to target and destroy tumors. The findings, published in Science Advances, highlight the importance of molecular arrangement in vaccine design.

由 AI 报道

In a recent meeting with the Cuban president, health experts presented progress on the Finlay Vaccine Institute's pneumococcal conjugate vaccine development program. This effort, led for over 20 years, aims to protect children and older adults from severe diseases caused by Streptococcus pneumoniae. The heptavalent Quimi-Vio® vaccine is already registered and shows positive results in reducing mortality.

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝